Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + CHP in Frontline Treatment of Chinese Patients With CD30+ PTCL
NCT05673785Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Takeda. Started Feb 2023; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05673785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673785.